Imatinib Completed Phase 2 Trials for Primary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00041041Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer